Legend Biotech (LEGN) Appoints Ying Huang to its Board
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors
December 30, 2021 8:30 AM ESTSOMERSET, N.J.--(BUSINESS WIRE)-- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotechs Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotechs Board of Directors. Dr. Huang will serve as a Class I director.
We are delighted to have Dr. Huang join our Board of Directors, said Sally Wang, Chairwoman of Legend Biotech. As Legend Biotechs Chief Executive Officer and Chief Financial Officer, Dr. Huang has been... More
